Novo Nordisk Pharmatech showing power of recombinant insulin human at Bioprocessing Summit Boston


Novo Nordisk Pharmatech showing power of recombinant insulin human at Bioprocessing Summit Boston


NovoNordics 150x58

News | Novo Nordisk Pharmatech A/S

JULY 25, 2018

Insulin Sales Manager David Hall and Product Manager Sara Goualdoni will lead the Novo Nordisk Pharmatech team at Booth 108 at the Sheraton Boston.

They will be showcasing the company’s new recombinant insulin as a key component in innovative biologics, with power to optimize cell density and viability in serum free growth media.

Upstream biomanufacturing

“The BioProcessing Summit allows us to speak directly to our core audience of those working in upstream bio manufacturing, R&D., BD, along with all those stakeholders involved in cell line and media development,” said Sara Goualdoni.

“We will be able to address their key concerns on bioprocess optimization: high cell viability and high productivity,” she commented.

“Our new recombinant insulin can form a key component in cGMP manufacture of monoclonal antibodies, virus vaccines, gene therapy products and many other biological drug products approved by regulatory bodies worldwide, including FDA and EMA,” Ms. Goualdoni added.

About Novo Nordisk Pharmatech

Novo Nordisk Pharmatech A/S was established in 1949 as FeF Chemicals, and now part of the Novo Nordisk pharmaceutical group since its acquisition in 1986. On September1, 2015, the company became Novo Nordisk Pharmatech A/S. It is the leading worldwide supplier of recombinant insulin for cell growth media and pharmaceutical grade quaternary ammonium compounds (Quats) for the pharmaceutical, biopharmaceutical and personal care industries.

All Novo Nordisk Pharmatech products are manufactured to cGMP standards. The company has distinguished itself for global regulatory compliance, consistent high quality, extensive regulatory documentation, continuous availability, security of its global supply chain and high levels of service and support.

For Financial Year 2016, Novo Nordisk Pharmatech reported world sales totalling 669 million Danish kroner (DEK) with more than half of all sales recorded in North America.

About BioProcessing Summit 2018

The Bioprocessing Summit convenes more than 1,000 international bioprocess professionals to share practical solutions for today’s bioprocess challenges.

The tenth anniversary BioProcessing Summit 2018 is a five -day event opening August 13 at the Sheraton Hotel, Boston, MA.

Since foundation the event has grown to include 17 distinct conferences with week-long programs on upstream and downstream processing, analytical development and quality, formulation and stability, cell and gene therapy production, and manufacturing.

Alongside the conference program, the Summit hosts short courses and training seminars that provide in-depth coverage of critical bioprocess topics.

The event is organized by CHI with more information available at: http://www.bioprocessingsummit.com/

Media Contact

Vanessa León, Marketing Manager, Novo Nordisk Pharmatech A/S
Tel:+45 404 262 84
Email: vnlt@novonordiskpharmatech.com

Resources

Click on Novo Nordisk Pharmatech at Bioprocessing Summit, Boston for more information.
Click on Novo Nordisk Pharmatech to contact the company directly.
Click on Increasing viable CHO cell density for further information.


Supplier Information
Supplier: Novo Nordisk Pharmatech A/S
Address: Koebenhavnsvej 216, 4600 Koege, Denmark
Tel: +45 566 71000
Fax: + 33 38 331 2483
Website: http://novonordiskpharmatech.com/


Comments are closed.